Recently, the nuclear factor erythroid 2-related factor 2 (Nrf2) activator bardoxolone methyl (CDDO-Me) has been shown to exert a renal-protective effect on individuals with diabetic nephropathy, mainly through antioxidant and anti-inflammatory effects (TSUBAKI study) [15]. Here, NFE2L2 is linked to diabetic kidney disease.